I’ve been blogging about stem cells now for about 8 years and the recent level of hype about and fluffy media coverage of Celularity, the biotech spun out of Celgene, ranks right up here with the most extreme past cases I’ve seen. What is Celularity and who is its leadership? It’s a new biotech focused …
Just one word placentas: Can Celularity live up to hype? Read More »
From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently …
Update on stem cells & cell therapy for COVID trials Read More »
Many of you readers know tech guru Peter Diamandis for his great X PRIZE, but he’s also involved in the regenerative medicine world including a new effort called Fountain Life. Teaming up with life coach Tony Robbins and others for Fountain Life raises some red flags for me. What’s in this article Peter Diamandis and …
Review of Peter Diamandis Fountain Life clinics: more than stem cell hype? Read More »
It’s been a week with a wide variety of regenerative medicine papers and stem cell news. Here’s my earlier take from a few days ago on the Belmonte-led human-monkey chimeric embryo paper in Cell that broke this week. A few days ago I also put up a new video on our Stem Cell YouTube Channel …
Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell …
24 cell therapy & stem cell stocks I’m following Read More »
What a difference one day can make including in the types of questions I’m getting with this one rising to the top: should President Donald Trump get stem cells for his COVID-19? Whether he should or not, will he get them? This is more than a hypothetical as a surprising number of people in Trump’s …
In my view, it seems likely that the FDA has opened a big can of worms by starting to clear the COVID-19 trials and programs of for-profit stem cell clinics and other related firms. OK to Stemedica trial The FDA just approved another such effort, this one by the firm Stemedica. You can read more about …
FDA OK’s more COVID-19 efforts of unproven stem cell clinics Read More »
When you sit down to read science on the weekends lately, assuming you are not primarily a COVID-19 researcher, how much COVID stuff seeps into your reading? As I was going over some of this year’s recommended weekly reads posts here on The Niche, I’ve realized that an increasing amount of COVID-19 research has joined …
Recommended reads: PSC, COVID, FDA pledge, sci jobs Read More »
The FDA and its CBER branch have been doing a good job overall in the last 3+ years to tackle the unproven stem cell clinic problem, but lately on the stem cells for COVID-19 front there is reason for real concern. I believe the agency is taking on major risk overall by clearing a vast number of …
Politics & FDA OK of 2 stem cell clinic COVID-19 efforts Read More »
What are you reading these days and does it include topics like cell therapies for COVID-19, ALS, regenerative potential of fibroblasts, and why Zoom meetings are so tiring for the brain? I cover those topics and more below with recommended reads including papers and media items. Here’s last week’s recommended reads. Here’s to fibroblasts, which …
Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain Read More »